FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
9 Tips for Avoiding Tax Season Cyber Scams 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
